Effects of a new cardioselective beta-adrenergic blocker (tolamolol) on exercise tolerance in patients with angina pectoris.
D000433:1-Propanol / Q000627:therapeutic use; D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D000605:Amino Alcohols / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy*; D001549:Benzamides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003408:Cresols / Q000627:therapeutic use; D003864:Depression, Chemical; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion / Q000187:drug effects*; D011433:Propranolol / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D001549:Benzamides; D003408:Cresols; D000433:1-Propanol; D011433:Propranolol